14 results on '"Pisano, Carmela"'
Search Results
2. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
- Author
-
Ventriglia, Jole, Paciolla, Immacolata, Pisano, Carmela, Cecere, Sabrina Chiara, Di Napoli, Marilena, Tambaro, Rosa, Califano, Daniela, Losito, Simona, Scognamiglio, Giosuè, Setola, Sergio Venanzio, Arenare, Laura, Pignata, Sandro, and Della Pepa, Chiara
- Abstract
The tumors of the female genital tract represent a leading cause of morbidity and mortality among women worldwide. Substantial progresses have been made in ovarian cancer, with the increasing knowledge about BRCA mutated tumors and the recent development of PARP inhibitors, and in cervical cancer, thanks to extensive screening and widespread of vaccination against Human Papilloma Virus. Nevertheless many needs remain unmet, advanced stage diseases are still incurable and cervical and endometrial carcinoma, as well as platinum-resistant ovarian carcinoma, can certainly be classifiable among the cancers with poor sensitivity to conventional chemotherapy. Immunotherapy, including a number of approaches, checkpoint inhibitors, adoptive cellular transfer, vaccines, has experienced a remarkable growth in the last few years and it is already an available option in melanoma, lung and renal malignancies. We reviewed the main findings about the immune microenvironment in ovarian, endometrial and cervical cancer with a special focus on the clinical data, the therapeutic implications and the most promising novel agents. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
- Author
-
Della Pepa, Chiara, Tonini, Giuseppe, Santini, Daniele, Losito, Simona, Pisano, Carmela, Di Napoli, Marilena, Cecere, Sabrina Chiara, Gargiulo, Piera, and Pignata, Sandro
- Abstract
Low Grade Serous Ovarian Carcinoma, LGSOC, is certainly a rare disease, accounting for only a small proportion of all ovarian carcinomas, nevertheless in the last decade we have acquired many data about its molecular and clinical features and it has been largely accepted that it has distinct pathogenesis, genetic aberrations and clinical behavior compared to High Grade Serous Ovarian Carcinoma, HGSOC, which is the most common ovarian cancer histotype. A large number of series pointed out the high rate of KRAS and BRAF mutations in LGSOCs and Serous Borderline Tumors, SBLTs, in contrast with their rarity in HGSOC. Such finding, together with the recurrent observation of focus of LGSOC associated with areas of SBLT in the same lesion, led to abandon the traditional histology classification, defining three types of serous carcinomas, in favor of a new dualistic grading system which recognizes only LG and HG carcinomas corresponding to distinct tumorigenesis pathways, the former based on KRAS/BRAF mutations and alteration of the MAP/ERK signaling, the latter characterized by early genetic instability and wild type status of KRAS and BRAF. LGSOC shows favorable overall survival, compared to general ovarian cancer population, but worrying resistance to conventional treatments. MEK inhibitors are emerging as active agents and may well represent an effective therapeutic strategy in the near future. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Immunotherapy in cervix cancer.
- Author
-
Attademo, Laura, Tuninetti, Valentina, Pisano, Carmela, Cecere, Sabrina Chiara, Di Napoli, Marilena, Tambaro, Rosa, Valabrega, Giorgio, Musacchio, Lucia, Setola, Sergio Venanzio, Piccirillo, Patrizia, Califano, Daniela, Spina, Anna, Losito, Simona, Greggi, Stefano, and Pignata, Sandro
- Abstract
The treatment approach to cervix cancer has remained unchanged for several decades and new therapeutic strategies are now required to improve outcomes, as the prognosis is still poor. In the last years, a better understanding of HPV tumor-host immune system interactions and the development of new therapeutics targeting immune checkpoints generated interest in the use of immunotherapy in cervix cancer. Preliminary phase I-II trials demonstrated the efficacy, the duration of responses and the manageable safety of this approach. Currently, many phase II and III studies are ongoing in both locally advanced and metastatic cervical cancer, assessing immunotherapy as a single agent or in combination with chemotherapy and radiotherapy. We reviewed the published data and the therapeutic implications of the most promising novel immunotherapeutic agents under investigation in cervix cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
- Author
-
Pignata, Sandro, Scambia, Giovanni, Schettino, Clorinda, Arenare, Laura, Pisano, Carmela, Lombardi, Davide, De Giorgi, Ugo, Andreetta, Claudia, Cinieri, Saverio, De Angelis, Carmine, Priolo, Domenico, Casanova, Claudia, Rosati, Marta, Greco, Filippo, Zafarana, Elena, Schiavetto, Ilaria, Mammoliti, Serafina, Cecere, Sabrina Chiara, Salutari, Vanda, and Scalone, Simona
- Subjects
- *
ENDOMETRIAL cancer , *PACLITAXEL , *CARBOPLATIN , *PROGRESSION-free survival , *MEDICAL personnel - Abstract
Adding immunotherapy to first-line chemotherapy might improve outcomes for patients with advanced or recurrent endometrial cancer. We aimed to compare carboplatin and paclitaxel versus avelumab plus carboplatin and paclitaxel as first-line treatment with avelumab given concurrent to chemotherapy and as maintenance after the end of chemotherapy. MITO END-3 is an open-label, randomised, controlled, phase 2 trial conducted at 31 cancer institutes, hospitals, and universities in Italy. Eligible patients were aged 18 years or older with histologically confirmed advanced (FIGO stage III–IV) or recurrent endometrial cancer, an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, and no previous systemic anticancer therapy as primary treatment for advanced or metastatic disease. Participants were randomly assigned (1:1) using a computerised minimisation procedure stratified by centre, histology, and stage at study entry, to either receive carboplatin (area under the curve [AUC] 5 mg/mL × min) and paclitaxel (175 mg/m2; standard group) intravenously every 3 weeks for six to eight cycles or avelumab (10 mg/kg intravenously) added to carboplatin and paclitaxel (experimental group) every 3 weeks and then every 2 weeks as a single maintenance treatment after the end of chemotherapy until disease progression or unacceptable toxicity. Patients, treating clinicians, and those assessing radiological examinations were not masked to study treatment. The primary endpoint was investigator-assessed progression-free survival, measured in the intention-to-treat (ITT) population. Patients who received at least one dose of study drug were included in the safety analysis. Experimental group superiority was tested with 80% power and one-tailed α 0·20. This trial is registered with ClinicalTrials.gov (NCT03503786) and EudraCT (2016–004403–31). From April 9, 2018, to May 13, 2021, 166 women were assessed for eligibility and 39 were excluded. 125 eligible patients were randomly assigned to receive carboplatin and paclitaxel (n=62) or avelumab plus carboplatin and paclitaxel (n=63) and included in the ITT population. The median follow-up was 23·3 months (IQR 13·2–29·6) and was similar between the two groups. 91 progression-free survival events were reported, with 49 events in 62 patients in the standard group and 42 events in 63 patients in the experimental group. The median progression-free survival was 9·9 months (95% CI 6·7–12·1) in the standard group and 9·6 months (7·2–17·7) in the experimental group (HR of progression or death 0·78 [60% CI 0·65–0·93]; one-tailed p=0·085). Serious adverse events were reported more frequently in the experimental group (24 vs seven events in the standard group); neutrophil count decrease was the most frequent grade 3–4 adverse event (19 [31%] of 61 patients in the experimental group vs 26 [43%] of 61 patients in the standard group). Two deaths occurred in the experimental group during treatment (one respiratory failure following severe myositis [possibly related to treatment] and one cardiac arrest [not related to treatment]). Adding avelumab to first-line chemotherapy deserves further testing in patients with advanced or recurrent endometrial cancer, although consideration of mismatch repair status is warranted. Pfizer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
- Author
-
Roma, Cristin, Esposito Abate, Riziero, Sacco, Alessandra, Califano, Daniela, Arenare, Laura, Bergantino, Francesca, Pisano, Carmela, Cecere, Sabrina Chiara, Scambia, Giovanni, Lorusso, Domenica, Artioli, Grazia, Tasca, Giulia, Spina, Anna, Russo, Daniela, Gadducci, Angiolo, De Angelis, Carmine, Bologna, Alessandra, Marchini, Sergio, Capoluongo, Ettore Domenico, and Perrone, Francesco
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *DNA analysis , *METABOLIC disorders , *BRCA genes , *OVARIAN tumors , *ENZYME inhibitors , *CANCER patients , *DNA repair , *GENETIC mutation , *PROGRESSION-free survival , *SEQUENCE analysis , *OVERALL survival , *GENETIC testing - Abstract
Homologous Recombination Deficiency (HRD) status predicts response to treatment with poly(ADP-ribose) polymerase inhibitors in Ovarian Cancer (OC) patients. The Myriad myChoiceCDx Assay is approved by Food and Drug Agency for the HRD assessment. Here we compared the HRD status obtained by three commercial panels with the results from Myriad reference test. The HRD analysis was performed on DNA from formalin-fixed and paraffin-embedded tumor samples of 100 untreated OC patients for which Myriad assay results were available, using TruSight Oncology 500 HRD assay (Illumina), Oncomine Comprehensive Assay Plus (Thermo Fisher Scientific) and SOPHiA DDM HRD solution panel (SOPHiA Genetics). A good overall concordance with the reference method was demonstrated at three different levels: BRCA mutational status (from 94.4 % to 97.7 %), the genomic instability value (from 88.2 % to 95.3 %) and for the HRD status (from 90.4 % to 97.6 %). Moreover, a trend in favour of HRD positive patients for response rate, progression-free survival and overall survival similar to Myriad was observed for all three tests. Our data suggest the feasibility of commercial testing for assessing HRD status, with a good concordance with the reference method and association with clinical outcome. • Harmonization of HRD assays is crucial for PARPi therapy in ovarian cancer. • HRD commercial assays have a good a good agreement rate with the reference test. • The commercial tests show a correlation with outcome similar to reference assay. • Discordance was observed in BRCA classification of variants. • Genomic instability scores close to cut-off should be discussed in the tumor board. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
- Author
-
Tuninetti, Valentina, Virano, Elisa, Salutari, Vanda, Ricotti, Andrea, Pisano, Carmela, Ducceschi, Monika, Turitto, Giacinto, Scandurra, Giuseppa, Petrella, Maria Cristina, Forestieri, Valeria, Rizzetto, Monica, Mammoliti, Serafina, Artioli, Grazia, Cioffi, Raffaella, Borsotti, Lucia, Bellero, Marco, Rognone, Chiara, Carbone, Vittoria, Ferrandina, Gabriella, and Mantiero, Mara
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *ANEMIA , *PATIENT safety , *DRUG side effects , *HYPERTENSION , *FATIGUE (Physiology) , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *MONOCLONAL antibodies , *LONGITUDINAL method , *DRUG efficacy , *RESEARCH , *PROGRESSION-free survival , *HEALTH outcome assessment , *OVERALL survival , *COMORBIDITY ,CERVIX uteri tumors - Abstract
cemiplimab is an immunoglobulin G4 monoclonal antibody targeting the programmed cell death-1 receptor. A nominal use program is available in Italy in advanced cervical cancer (CC) patients treated with platinum based chemotherapy based on the results of EMPOWER-Cervical 1/GOG-3016/ENGOTcx9 trial. This real-world, retrospective cohort, multicenter study aimed at describing clinical outcomes of patients with advanced CC treated with cemiplimab in Italy. The primary objective of the study was to assess the feasibility and the replicability of the initial results in a real world setting of cemiplimab nominal use. The primary endpoint of our analysis was progression free survival (PFS). Secondary endpoints included overall response rate (ORR), overall survival (OS) and safety data. From March 2022 to December 2023, 135 patients were treated in 12 Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) Centers. Forty-two percent of patients had one or more comorbidities, hypertension being the most common (23.4%). Median PFS was 4.0 months (range 3.0–6.0) and median OS was 12.0 months (12.0- NR) with no differences according to PD-L1 status. Complete response (CR) or no evidence of disease (NED) were observed in 8.6%; partial response (PR) in 21.1%, stable disease (SD) in 14.8% and progression was recorded in 44.5% of patients. Most common drug related adverse events (AEs) were anemia (39.1%) and fatigue (27.8%). Immune related AEs occurred in 18.0%. This study confirms the feasibility and the replicability of the cemiplimab nominal use in advanced CC, in a real-world practice in Italy. • Cemiplimab is an immunoglobulin G4 monoclonal antibody targeting PD-L1. • A nominal use program of cemiplimab is available in Italy for cervical cancer. • MITO44 is a real-world, retrospective cohort, multicenter study. • MITO44 confirms the feasibility of the cemiplimab nominal use in cervical cancer. • PFS, ORR, OS and safety favorably compared to experimental data. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
- Author
-
Tjokrowidjaja, Angelina, Lee, Chee K., Friedlander, Michael, Gebski, Val, Gladieff, Laurence, Ledermann, Jonathan, Penson, Richard, Oza, Amit, Korach, Jacob, Huzarski, Tomasz, Manso, Luis, Pisano, Carmela, Asher, Rebecca, Lord, Sarah J., Kim, Se Ik, Lee, Jung-Yun, Colombo, Nicoletta, Park-Simon, Tjoung-Won, Fujiwara, Keiichi, and Sonke, Gabe
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *COMPUTED tomography , *CONFIDENCE intervals , *DIAGNOSTIC errors , *ENZYME inhibitors , *GENETIC mutation , *OVARIAN tumors , *TUMOR antigens , *SECONDARY analysis , *BRCA genes , *PREDICTIVE tests , *DISEASE progression , *DESCRIPTIVE statistics - Abstract
Limited evidence exists to support CA-125 as a valid surrogate biomarker for progression in patients with ovarian cancer on maintenance PARP inhibitor (PARPi) therapy. We aimed to assess the concordance between CA-125 and Response Evaluation Criteria in Solid Tumours (RECIST) criteria for progression in patients with BRCA mutations on maintenance PARPi or placebo. We extracted data on progression as defined by Gynecologic Cancer InterGroup CA-125, investigator- and independent central-assessed RECIST from the SOLO2/ENGOT-ov21(NCT01874353) trial. We excluded those with progression other than by RECIST, progression on date of randomisation, and no repeat CA-125 beyond baseline. We evaluated the concordance between CA-125 progression and RECIST progression, and assessed the negative (NPV) and positive predictive value (PPV). Of 295 randomised patients, 275 (184 olaparib, 91 placebo) were included. 171 patients had investigator-assessed RECIST progression. Of 80 patients with CA-125 progression, 77 had concordant RECIST progression (PPV 96%, 95% confidence interval 90–99%). Of 195 patients without CA-125 progression, 94 had RECIST progression (NPV 52%, 45–59%). Within treatment arms, PPV was similar (olaparib: 95% [84–99%], placebo: 97% [87–100%]) but NPV was lower in patients on placebo (olaparib: 60% [52–68%], placebo: 30% [20–44%]). Of 94 patients with RECIST but without CA-125 progression, 64 (68%) had CA-125 that remained within normal range. We observed similar findings using independent-assessed RECIST. Almost half the patients without CA-125 progression had RECIST progression, and most of these had CA-125 within the normal range. Regular computed tomography imaging should be considered as part of surveillance in patients treated with or without maintenance olaparib rather than relying on CA-125 alone. • There is poor concordance between CA-125 non-PD and RECIST progression. • Half the patients without CA-125 PD had RECIST PD, most had normal CA-125 levels. • CT imaging to be considered as part of follow-up rather than relying on CA-125 alone. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
- Author
-
Pignata, Sandro, Lorusso, Domenica, Scambia, Giovanni, Sambataro, Daniela, Tamberi, Stefano, Cinieri, Saverio, Mosconi, Anna M, Orditura, Michele, Brandes, Alba A, Arcangeli, Valentina, Panici, Pierluigi Beneditti, Pisano, Carmela, Cecere, Sabrina C, Di Napoli, Marilena, Raspagliesi, Francesco, Maltese, Giuseppa, Salutari, Vanda, Ricci, Caterina, Daniele, Gennaro, and Piccirillo, Maria Carmela
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *PACLITAXEL , *OVARIAN cancer , *PLATINUM , *RANDOMIZED controlled trials , *THERAPEUTICS - Abstract
Summary Background Inhibition of angiogenesis is a valuable treatment strategy for ovarian cancer. Pazopanib is an anti-angiogenic drug active in ovarian cancer. We assessed the effect of adding pazopanib to paclitaxel for patients with platinum-resistant or platinum-refractory advanced ovarian cancer. Methods We did this open-label, randomised phase 2 trial at 11 hospitals in Italy. We included patients with platinum-resistant or platinum-refractory ovarian cancer previously treated with a maximum of two lines of chemotherapy, Eastern Cooperative Oncology Group performance status 0–1, and no residual peripheral neurotoxicity. Patients were randomly assigned (1:1) to receive weekly paclitaxel 80 mg/m 2 with or without pazopanib 800 mg daily, and stratified by centre, number of previous lines of chemotherapy, and platinum-free interval status. The primary endpoint was progression-free survival, assessed in the modified intention-to-treat population. This trial is registered with ClinicalTrials.gov , number NCT01644825 . This report is the final analysis; the trial is completed. Findings Between Dec 15, 2010, and Feb 8, 2013, we enrolled 74 patients: 37 were randomly assigned to receive paclitaxel and pazopanib and 37 were randomly assigned to receive paclitaxel only. One patient, in the paclitaxel only group, withdrew from the study and was excluded from analyses. Median follow-up was 16·1 months (IQR 12·5–20·8). Progression-free survival was significantly longer in the pazopanib plus paclitaxel group than in the paclitaxel only group (median 6·35 months [95% CI 5·36–11·02] vs 3·49 months [2·01–5·66]; hazard ratio 0·42 [95% CI 0·25–0·69]; p=0·0002). We recorded no unexpected toxic effects or deaths from toxic effects. Adverse events were more common in the pazopanib and paclitaxel group than in the paclitaxel only group. The most common grade 3–4 adverse events were neutropenia (11 [30%] in the pazopanib group vs one [3%] in the paclitaxel group), fatigue (four [11%] vs two [6%]), leucopenia (four [11%] vs one [3%]), hypertension (three [8%] vs none [0%]), raised aspartate aminotransferase or alanine aminotransferase (three [8%] vs none), and anaemia (two [5%] vs five [14%]). One patient in the pazopanib group had ileal perforation. Interpretation Our findings suggest that a phase 3 study of the combination of weekly paclitaxel plus pazopanib for patients with platinum-resistant or platinum-refractory advanced ovarian cancer is warranted. Funding National Cancer Institute of Napoli and GlaxoSmithKline. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. Chemotherapy in epithelial ovarian cancer
- Author
-
Pignata, Sandro, Cannella, Lucia, Leopardo, Davide, Pisano, Carmela, Bruni, Giovanni Salvatore, and Facchini, Gaetano
- Subjects
- *
CANCER chemotherapy , *OVARIAN cancer , *EPITHELIAL cells , *DISEASES in older women , *ADJUVANT treatment of cancer , *ANTINEOPLASTIC agents - Abstract
Abstract: Epithelial ovarian cancer is the most common type of ovarian cancer; usually occurs in women older than 50years, and because 75% of cases are diagnosed at stage III or IV it is associated with a poor prognosis. Treatment of ovarian cancer is based on the integration of surgery and chemotherapy. Chemotherapy plays a major role both in the adjuvant treatment and in the care of patients with advanced disease. Several active drugs have been introduced in the treatment of ovarian cancer in the last decades and novel targets and agents are under evaluation. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
11. Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer
- Author
-
Pignata, Sandro, Lauraine, Eric Pujade, du Bois, Andreas, and Pisano, Carmela
- Subjects
- *
LIPOSOMES , *DOXORUBICIN , *ANTHRACYCLINES , *NEUROTOXIC agents , *CANCER chemotherapy , *CANCER treatment , *OVARIAN cancer - Abstract
Abstract: Objective: Many questions remain unanswered regarding the optimal treatment paradigm for ovarian cancer, and alternatives for both first- and second-line therapy are needed. Methods: This review summarizes recent data with the combination of pegylated liposomal doxorubicin (PLD) and carboplatin in ovarian cancer. Results: Anthracyclines are active in ovarian cancer and lack the neurotoxic effects of taxanes. PLD has reduced cardiotoxic potential vs non-liposomal doxorubicin and is the only non-platinum monotherapy to demonstrate a significant survival advantage as second-line treatment of ovarian cancer. Replacing the taxane with PLD in platinum doublets for either first-line or recurrent ovarian cancer (ROC) has been or is being evaluated in more than 1600 patients. Studies evaluating PLD plus carboplatin in platinum-sensitive ROC have shown that the regimen is tolerable and active. Conclusion: PLD–carboplatin is a promising chemotherapy combination. Phase III trials will elucidate whether it represents a new standard of care in ovarian cancer. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
12. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer: A Multicentre Italian Trial in Ovarian cancer (MITO-5) study
- Author
-
Pignata, Sandro, Breda, Enrico, Scambia, Giovanni, Pisano, Carmela, Zagonel, Vittorina, Lorusso, Domenica, Greggi, Stefano, De Vivo, Rocco, Ferrandina, Gabriella, Gallo, Ciro, and Perrone, Francesco
- Subjects
- *
PACLITAXEL , *TREATMENT of diseases in older people , *CANCER chemotherapy , *OVARIAN cancer - Abstract
Abstract: Background: Carboplatin/paclitaxel every 3 weeks is the standard for patients with ovarian cancer, but elderly patients frequently receive modified schedules or single agent chemotherapy to avoid toxicity. A phase II study was conducted to describe tolerability of a weekly schedule of both drugs in elderly patients. Methods: Patients aged ≥70 years with stage IC-IV ovarian cancer, performance status ≤2, were eligible. Treatment was carboplatin (AUC 2)+paclitaxel (60mg/m2) on days 1, 8, 15 every 4 weeks, up to six cycles. A two-stage design was applied with lack of unacceptable toxicity as primary endpoint; 26 patients were required at the final stage, with at least 23 of them without unacceptable toxicity to conclude for a positive result. Geriatric assessment was performed by activity daily living (ADL) and instrumental ADL (IADL) scales. Results: Twenty-six patients were analysed (median age 77 years, range 70–84). Performance status was 0 in 10 and 1 in 16 patients; 14 patients had two or more comorbidities; 8 and 18 patients had some dependency in ADL or IADL. Twenty-three patients (88.5%) were treated without suffering unacceptable toxicity. Unacceptable toxic events were grade 3 heart rhythm, grade 3 increase of liver transaminases and prolonged haematological toxicity. Grade 1 neuropathy was reported in four cases. Out of 13 patients evaluable by RECIST, 5 partial responses were observed (response rate 38.5%). Two complete responses were observed among six patients with non-target lesions. Eight patients eligible for CA-125 response assessment had a response after six cycles. Median estimated progression-free survival was 13.6 months, and median overall survival was 32.0 months. Conclusions: In a series of elderly ovarian cancer patients, characterized by a high incidence of comorbidities and functional impairment, weekly carboplatin and paclitaxel demonstrated a favourable toxicity profile. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
13. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer
- Author
-
Tambaro, Rosa, Scambia, Giovanni, Di Maio, Massimo, Pisano, Carmela, Barletta, Emiddio, Iaffaioli, Vincenzo Rosario, and Pignata, Sandro
- Subjects
- *
CERVICAL cancer , *RADIOTHERAPY , *DRUG therapy , *CISPLATIN - Abstract
Cervical cancer is among the major health problems world-wide although advances in screening programs. Surgery and radiotherapy are the treatment modalities of choice for early and locally advanced cervical cancer. However, the role of chemotherapy in this setting has been better investigated in the latest years. To improve loco-regional control in locally advanced disease, authors have tested both neo-adjuvant chemotherapy and concurrent chemoradiotherapy. From 1999 NCI clinical announcement, concurrent cisplatin-based chemoradiation is considered the treatment of choice for cervical cancer patients requiring radiation therapy. Neo-adjuvant chemotherapy is reaching encouraging results in IB bulky-IIA cervical cancer, but further investigation are ongoing in locally advanced cervical setting. The optimal treatment for patients with metastatic or recurrent cervical cancer is still undefined and chemotherapy is used with palliation intent. Cisplatin remains the most active cytotoxic agents, although combinations of cisplatin with paclitaxel, topotecan, vinorelbine, have shown encouraging results in phase II and in early phase III studies. This paper reviews the role of chemotherapy in the management of patients with locally advanced, metastatic and recurrent cervical cancer. Studies discussed in this paper were selected trough a search in the med-line database performed in October 2003. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
14. Corrigendum to “Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer” [Crit. Rev. Oncol./Hematol. 73 (2010) 23–30]
- Author
-
Pignata, Sandro, Lauraine, Eric Pujade, du Bois, Andreas, and Pisano, Carmela
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.